Evolving Landscape of First-Line Therapies in Metastatic RCC: Cabozantinib-Based Approaches

Panelists discuss how the first-line treatment landscape for metastatic renal cell carcinoma has evolved in recent years, considering various factors that influence decision-making for newly diagnosed patients.

Panelists discuss how the efficacy and safety profiles of various treatment options for intermediate/poor-risk metastatic renal cell carcinoma compare, including cabozantinib monotherapy, nivolumab plus cabozantinib combination, nivolumab plus ipilimumab combination, and other immune checkpoint inhibitor plus tyrosine kinase inhibitor combinations.

Panelists discuss how they approach selecting among various immune checkpoint inhibitor (ICI) plus tyrosine kinase inhibitor (TKI) combinations for first-line treatment of metastatic renal cell carcinoma, considering key factors that influence their decision-making process and drawing insights from recent clinical trials such as CheckMate 9ER, KEYNOTE-426, and CLEAR.

Panelists discuss how specific disease characteristics, such as tumor burden, metastatic sites, and risk stratification, most strongly influence their decision-making process when choosing between immune checkpoint inhibitor plus tyrosine kinase inhibitor (ICI plus TKI) regimens and dual immune checkpoint inhibitor (ICI plus ICI) combinations for treating metastatic renal cell carcinoma.

Panelists discuss how the management of adverse events differs between tyrosine kinase inhibitor (TKI) monotherapy and immune checkpoint inhibitor plus TKI (ICI+TKI) combinations, including any notable differences in adverse effect profiles among various ICI plus TKI regimens used in treating metastatic renal cell carcinoma.

Panelists discuss how the introduction of adjuvant immunotherapy has influenced their first-line treatment decisions for patients with newly diagnosed metastatic renal cell carcinoma.

Panelists discuss how they balance efficacy outcomes like overall survival and progression-free survival against tolerability and quality of life considerations when making decisions about first-line treatment for metastatic renal cell carcinoma patients.

Panelists discuss how unmet needs persist in first-line treatment of metastatic renal cell carcinoma, exploring anticipated advances in tyrosine kinase inhibitor–based therapies and other novel approaches that may address these challenges in the coming years.